Oncoinvent ASA (LON:0RU5)
London · Delayed Price · Currency is GBP · Price in NOK 42.50
-0.06 (-0.13%)
Feb 10, 2026, 11:47 AM GMT
Oncoinvent ASA Revenue
Oncoinvent ASA had revenue of 5.98M NOK in the quarter ending June 30, 2025, with 17,750.75% growth. This brings the company's revenue in the last twelve months to 20.00M, up 247.12% year-over-year. In the year 2024, Oncoinvent ASA had annual revenue of 8.10M with 39.95% growth.
Revenue (ttm)
20.00M NOK
Revenue Growth
+247.12%
P/S Ratio
10.28
Revenue / Employee
555.44K NOK
Employees
36
Market Cap
14.83M GBP
Revenue Chart
* This company reports financials in NOK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.10M | 2.31M | 39.95% |
| Dec 31, 2023 | 5.79M | -493.00K | -7.85% |
| Dec 31, 2022 | 6.28M | -4.80M | -43.31% |
| Dec 31, 2021 | 11.08M | 705.85K | 6.80% |
| Dec 31, 2020 | 10.38M | -1.03M | -9.06% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.02B |
| Smith & Nephew | 4.33B |
| Inspiration Healthcare Group | 45.20M |
| Cambridge Cognition Holdings | 9.05M |
| CelLBxHealth | 2.62M |
| Renalytix | 2.19M |
Oncoinvent ASA News
- 3 months ago - Oncoinvent ASA (BRRGF) M&A Call Transcript - Seeking Alpha
- 1 year ago - BerGenBio ASA (STU:7BG0) Q4 2024 Earnings Call Highlights: Strategic Review and Financial ... - GuruFocus